Educational Background

Macalester College, B.A., Biology (cum laude), 2006

University of Minnesota Medical School, M.D., 2011

Residency: Internal Medicine, University of Washington, 2011–2014

Fellowship: Pulmonary, Critical Care & Sleep Medicine, University of Washington, 2015–2018

Professional Career

Assistant Professor of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine, University of Washington. Principal Investigator of an NIH-funded pulmonary vascular biology laboratory. Medical Director of the UW Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program and Associate Director of the UW Hereditary Hemorrhagic Telangiectasia (HHT) Center.

Research Field

In vitro modeling of pulmonary arterial hypertension using bioengineered vascular platforms

Hemodynamic forces and pulmonary endothelial dysfunction

Translational multi-omics in pulmonary arterial hypertension

Diagnosis and management of chronic thromboembolic pulmonary hypertension

Papers, Books, etc.

Author of 44 peer-reviewed publications spanning pulmonary vascular disease, vascular biology, and related fields. Selected highlights:

Rayner SG et al. Multiphoton-guided Creation of Complex Organ-specific Microvasculature. Adv Healthc Mater. 2021.

Rayner SG et al. Zone of Uncertainty in Pulmonary Arterial Wedge Pressure Measurement. Am J Respir Crit Care Med. 2024.

Hirsch K*, Mandrycky CJ*, Kwan I, …Rayner SG. Endothelial Responses to Shear Stress and Pressure in PAH. bioRxiv. 2025 (under review).

Educational Background

Apr 1982- Mar 1988 MD; Okayama University Medical School

May 1988- Apr 1990 National Okayama Hospital, Department of Internal Medicine, Residency

May 1990- Apr 1993 National Cardiovascular Center, Department of Cardiology, Residency

Sep 2000 PhD; Okayama University Graduate School of Medicine and Dentistry

Professional Career

Okayama University Graduate School of Medicine and Dentistry, Department of Cardiology; Associate Professor (May 2000- Apr 2003)

National Hospital Organization, Okayama Medical Center, Department of Cardiology; Director (May 2003- Mar 2020, Department of Clinical Science; Director (May 2010- Mar 2019)

Entire Medical Departments; Director (Apr 2019 - Mar 2021), Vice President (Apr 2021 – active)

Research Field

clinical and physiological aspects of pulmonary hypertension

diagnosis and treatment of Group I PH

Interventional treatment of Group IV PH

Papers, Books, etc.

J Heart Lung Transplant. 2025. doi: 10.1016/j.healun.2025.10.031

Lancet Respir Med. 2025. doi: 10.1016/S2213-2600(25)00127-4

Circ Cardiovasc Interv. 2025. doi: 10.1161/CIRCINTERVENTIONS.125.016172

J Am Coll Cardiol. 2025;85:2270-2284. doi: 10.1016/j.jacc.2025.04.021

Clin Nucl Med. 2025;50:623-630. doi: 10.1097/RLU.0000000000005919

Educational Background

Medical Graduate 2006 – 2012 Doctor of Medicine Keio University School of Medicine, Tokyo, JAPAN

Doctoral Course 2017 – 2020 Doctor of Philosophy Keio University School of Medicine, Tokyo, JAPAN

Professional Career

Residency 2012 - 2014 Internal Medicine Keio University Hospital, Tokyo, JAPAN

Fellowship 2014 - 2017 Cardiology Yokohama Citizen’s Municipal Hospital Kanagawa, JAPAN

Research Fellowship 2017 - 2020 Cardiology Keio University School of Medicine, Tokyo, JAPAN

Postdoctoral Fellowship 2021 – Present Cardiology Keio University School of Medicine, Tokyo, JAPAN

Fellowship 2025 – Present Medical genomics National Cerebral and Cardiovascular Center, Osaka, JAPAN

Research Field

I have focused on understanding the molecular mechanisms of pulmonary hypertension, right ventricular dysfunction, cardiac hypertrophy, and vascular diseases. I have conducted extensive basic researches on developing new therapies for the treatment of pulmonary arterial hypertension (PAH) using gene-editing technologies. My current role as a clinical physician at Keio University Hospital allows me to combine clinical practice with my research endeavors.
My researches have been recognized with several awards, including the “Best Young Investigator’s Award” and “Outstanding Research Award” from the Japan Cardiovascular Society, the “Young Researcher Award” from the European Society of Cardiology Pulmonary Circulation and Right Ventricular Function Working Group, the “Moderated Poster Presentation Winner” from the European Society of Cardiology, the “Oral Presentation Award” at the 1st Asian Cardiovascular Symposium at Basic Cardiovascular Sciences held in the USA, and the “Best Young Investigator’s Award” at the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Conference.

Papers, Books, etc.

Hiraide T, Tsuda N, Momoi M, et al. CXCL12/CXCR4 pathway as a novel therapeutic target for RNF213-associated pulmonary arterial hypertension. Sci Rep. 2024;14:26604.

Hiraide T, Suzuki H, Momoi M, et al. RNF213-associated vascular disease: a concept unifying various vasculopathies. Life. 2022;12:555.

Hiraide T, Kataoka M, Suzuki H, et al. Poor outcomes in carriers of the RNF213 variant (p.Arg4810Lys) with pulmonary arterial hypertension. J Heart Lung Transplant. 2020;39:103–112.

Hiraide T, Kataoka M, Suzuki H, Aimi Y, Chiba T, Kanekura K, Satoh T, Fukuda K, Gamou S, Kosaki K. SOX17 mutations in Japanese patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2018;198:1231–1233.

Hiraide T, Teratani T, Uemura S, et al. Pulmonary arterial hypertension caused by AhR signal activation protecting against colitis. Am J Respir Crit Care Med. 2021;203:385–388.

Educational Background

MBBS, University of Queensland, 1996

BMedSc (with Distinction), Physiology and Pharmacology, University of Queensland, 1995

FRACP, Royal Australasian College of Physicians, 2005

Transplant and Pulmonary Hypertension Fellowship, The Prince Charles Hospital, 2005

Professional Career

Thoracic and Sleep Disorders Physician; Pulmonary Hypertension Specialist, 2005-Present

Lead Physician, Pulmonary Vascular Disease Unit/QLTS, The Prince Charles Hospital, 2015-Present

Director, Wesley Pulmonary Hypertension Unit, Wesley Hospital, 2008-Present

Director, Pulmonary Hypertension Research Queensland, 2025-present

President, Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ), 2021-Present

Senior Lecturer in Medicine, University of Queensland, 2006–Present

Research Field

Phase 1 to 4 Clinical Trials

Clinical trials in Groups 1 to 4

Exercise in PHT and exercise MRI

Papers, Books, etc.

Kearney K et al. (incl. Feenstra J). Impact of left heart disease risk factors on outcomes in PAH therapy. Chest. 2024;165(4):967–977.

Feenstra J et al. Effectiveness of epoprostenol in PAH: findings of an Australian retrospective chart review. Intern Med J. 2020;50(11):1377–1384.

Anderson J et al. (incl. Feenstra J). Retrospective Validation of the REVEAL 2.0 Risk Score with the ANZ PH Registry. Chest. 2020;157(1):162–172.

Scalia GM et al. (incl. Feenstra J). ePLAR – echocardiographic pulmonary to left atrial ratio: a novel parameter to differentiate pre- and post-capillary PH. Int J Cardiol. 2016;212:379–386.

H-index: 10. ORCID: 0009-0006-2840-9272. Full publication list available on request.

Educational Background

She was a Vice-President of Japanese Pulmonary Circulation and Pulmonary Hypertension Society (JPCPHS) during 2015-2021. She graduated from Nagasaki University School of Medicine and obtained her Ph.D. from Osaka University Graduate School of Medicine.

Professional Career

From 1987, she worked at The Center for Cardiovascular Research, The Toronto Hospital, and since 1990, conducted research on signal transduction of cytokines and growth factors in cardiac myocytes at the Department of Cardiology, Osaka University Graduate School of Medicine.

She was appointed as Vice-President of Osaka University in 2014, and also worked as a Trustee of National Cerebral and Cardiovascular Center (2018-2024) and an Auditor of National Institute for Quantum Science and Technology, Japan (2020-2024).

Research Field

Although she has a longstanding interest in genetics and biological mechanisms of the development of cardiomyopathy, her research interests include pulmonary circulation and cardiopulmonary interrelations from the viewpoints of genetics and inflammation

Papers, Books, etc.

Over 100 reviewed basic and clinical research papers;

Successful treatment of severe combined post- and pre-capillary pulmonary hypertension in a patient with idiopathic restrictive cardiomyopathy. Pulm Circ. 2018 Jul-Sep;8(3)

Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2677-86. doi: 10.1073/pnas.1424774112.

The challenge of the "estrogen paradox" in pulmonary arterial hypertension. Circ J. 2013;77(8):1992-3.

Pulmonary arterial hypertension associated with chronic active Epstein-Barr virus infection. Intern Med. 2011;50(2):119-24.

Educational Background

1979/07 MD. NATIONAL DEFENSE MEDICAL UNIVERSITY

1995/07-1997/07 -Post-doctoral fellowship, Hospital of the University of Pennsylvania, USA

2015/02 & /06 -Master class of Pulmonary Vascular Disease, Bologna University Hospital, Bologna, Italy

Professional Career

2018/12- Director, Center for PH and PVD, CMUH, Taichung, Taiwan

2015/04-2027/04 -Chairperson, Taiwan Pulmonary Hypertension Association (TPHA)

Research Field

Pulmonary hypertension including clinical and genetic studies

Papers, Books, etc.

Pulmonary hypertension publication in recent 5 years

Liang K-W, Chang S-K, Chen Y-W, Tsai W-J, Wang K-Y*(corresponding author). A cluster of heritable pulmonary arterial hypertension cases in a family with all three siblings carrying the same novel AQP1 c.273C>G variant-a case report. Pulm Circ. 2023;e12211. https: //doi.org/10.1002/pul2.12211

I Hsin Tai, Tsung-Cheng Shyu, Kai-Sheng Hsieh, Ke-Wei Chen, Wan-Jane Tsai, Kuo-Yang Wang*(corresponding author). Case report: The impact of percutaneous atrial septal defect closure in pulmonary hypertension with co-existing cor triatriatum sinister and multiple cardiac comorbidities. Front. Cardiovasc. Med., 07 September 2022 Sec. Cardiovascular Therapeutics https://doi.org/10.3389/fcvm.2022.913391

Kae-Woei Liang, Sheng-Kai Chang, Yu-Wei Chen, Wei-Wen Lin, Kuo-Yang Wang*(corresponding author). Whole exome sequencing of patients with primary pulmonary arterial hypertension in central Taiwan. Front Cardiovasc Med. 22 June 2022, doi: 10.3389/fcvm.2022.911649

Liang KW, Wei HJ, Wang KY*(corresponding author). Sustained hemodynamic and clinical improvements for a patient with idiopathic pulmonary arterial hypertension over 1.5 years after balloon atrial septostomy: a case report. Front Cardiovasc Med. 2022 Apr 7;9:868123. doi:10.3389/fcvm.2022.868123. eCollection 2022

Educational Background

1993년 3월 ~ 1999년 2월 고려대학교 의과대학 의학사

2002년 3월 ~ 2004년 2월 고려대학교 의과대학 대학원 의학 석사 (내과학)

2004년 3월 ~ 2007년 2월 고려대학교 의과대학 대학원 의학 박사 (순환기내과)

Professional Career

1999년 3월 ~ 2000년 2월 고려대학교 병원 수련의

2000년 3월 ~ 2004년 2월 고려대학교 병원 내과 전공의

2004년 3월 ~ 2007년 2월 고려대학교 병원 순환기 내과 전임의/임상강사

2007년 5월 ~ 2009년 4월 Brigham and Women’s Hospital Research Fellow

2009년 5월 ~ 2010년 2월 인하대학교 병원 심장내과 임상강사

2010년 3월 ~ 2014년 2월 인하대학교 병원 심장내과 조교수

2014년 3월 ~ 2019년 2월 인하대학교 병원 심장내과 부교수

2018년 ~ 2019년 Brigham and Women’s Hospital Visiting Associate Professor

2019년 3월 ~ 현재 인하대학교 병원 심장내과 교수

학회

대한내과학회 현) 윤리위원

대한심장학회 현) 편집위원, 정책위원

한국심초음파학회 현) 홍보이사

대한심부전학회 현) 국제교류이사

대한고혈압학회 현) 홍보위원

Educational Background

Professor Aldalaan earned his medical degree from King Saud University. He completed residencies in internal medicine at King Faisal Specialist Hospital & Research Centre and Duke University Medical Center. He then completed a pulmonary and critical care fellowship at the University of Virginia.

Professional Career

Abdullah Moshin Aldalaan, MBBS, is Director of the Pulmonary Hypertension Program of Excellence and a Consultant Pulmonologist at the King Faisal Specialist Hospital & Research Centre in Riyadh, Saudi Arabia. He also serves as a Professor in the College of Medicine at Alfaisal University, also located in Riyadh. In addition to his current role as President of the Saudi Association for Pulmonary Hypertension, Dr. Aldalaan has held leadership positions in numerous professional societies focused on respiratory disease and has lectured nationally and internationally.

Research Field

Dr. Aldalaan established the lung transplant program at King Faisal Specialist Hospital & Research Centre in 2003. He also established the institution’s pulmonary hypertension (PH) treatment program, which is the only program in the area providing comprehensive diagnostic and therapeutic protocols for patients with PH. The program offers all available internationally recognized medical interventions for PH and has become a region-wide reference center for pulmonary hypertension education and treatment.

Papers, Books, etc. presented or published by your name

Dr. Aldalaan also is an active clinical trialist and has published more than 50 papers in peer-reviewed journals.

Recent publication of note:
Aldalaan A, Saleemi SA, Weheba I, et al. Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT). Pulm Circ. 2022;12:e12083, doi: 10.1002/pul2.12083.

Educational Background

Apr 1982- Mar 1988 MD; Okayama University Medical School

May 1988- Apr 1990 National Okayama Hospital, Department of Internal Medicine, Residency

May 1990- Apr 1993 National Cardiovascular Center, Department of Cardiology, Residency

Sep 2000 PhD; Okayama University Graduate School of Medicine and Dentistry

Professional Career

Okayama University Graduate School of Medicine and Dentistry, Department of Cardiology; Associate Professor (May 2000- Apr 2003)

National Hospital Organization, Okayama Medical Center, Department of Cardiology; Director (May 2003- Mar 2020, Department of Clinical Science; Director (May 2010- Mar 2019), Entire Medical Departments; Director (Apr 2019 - Mar 2021), Vice President (Apr 2021 – active)

Research Field

clinical and physiological aspects of pulmonary hypertension

diagnosis and treatment of Group I PH

Interventional treatment of Group IV PH

Papers, Books, etc. presented or published by your name

JACC Cardiovasc Interv. 2024;17:707-708. doi: 10.1016/j.jcin.2023.11.022

Eur Respir J. 2024. doi: 10.1183/13993003.01294-2024

Can J Cardiol. 2024. doi: 10.1016/j.cjca.2024.05.003

J Heart Lung Transplant. 2024. doi: 10.1016/j.healun.2024.05.007

Circulation. 2024. doi: 10.1161/CIRCULATIONAHA.124.068610

Educational Background

Prof. Dr. med. Stephan Rosenkranz completed his Doctoral dissertation at Justus-Liebig-Universität Gießen, Gießen, Germany; a Post-doctoral fellowship at Harvard Medical School, Boston, Massachusetts, USA; and a residency and research fellowship at the Klinik III für Innere Medizin (Dept. of Cardiology), University of Cologne, Germany.

Professional Career

Prof. Dr. med. Stephan Rosenkranz currently holds the posts of Chair, Cologne Cardiovascular Research Center (CCRC); Full Professor of Cardiology (“Cardiopulmonary interaction”), University of Cologne; Head of Expert Center on Pulmonary Hypertension; Associate editor of European Journal of Heart Failure, Cardiovascular Research, Current Heart Failure Reports; and as a reviewer for numerous scientific journals, including Journal of the American Medical Association, Lancet, European Heart Journal.

Research Field

Prof. Dr. med. Stephan Rosenkranz has experience in numerous clinical trials in the field of heart failure and pulmonary hypertension (phase I, II, III, IV) and is Head ("Principal Investigator") of the working group on "Molecular Cardiology," with a research focus of Signal transduction and pathobiological relevance of tyrosine kinases in cardiovascular disease.

Papers, Books, etc. presented or published by your name

Most recently: Rosenkranz S, Ghofrani HA, Hoeper MM, et al. Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials [published correction appears in J Heart Lung Transplant. 2025:S1053-2498(25)01764-4. doi: 10.1016/j.healun.2025.02.1679.].
J Heart Lung Transplant. 2025;44(2):135-146. doi:10.1016/j.healun.2024.08.018

Educational Background

Visiting Scholar , University of Chicago Medical Center

PhD, Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan

Master Degree, Pulmonary Vascular Disease, University of Bologna, Bologna, Italy

MD, China Medical College, Taichung, Taiwan

Professional Career

2022- Professor, National Cheng Kung University

2023-, Deputy Superintendent, National Cheng Kung University Hospital

2020-2023 Medical Secretory, National Cheng Kung University Hospital

2019-2020 Deputy Superintendent, National Cheng Kung University Hospital Dou-Liou Branch

2004 Attending Physician, National Cheng Kung University Hospital

Research Field

Pulmonary Hypertension

Heart Failure

Heart Transplant Care

Critical Care

Post Resuscitation Care

Educational Background

1991.3 Graduate from Kyushu University School of Medicine

1993.6-1995.5 Research Fellow, Cardiovascular Medicine, Kyushu University

1998.10-2001.11 Research Fellow, Brigham and Women’s Hospital, Harvard Medical School

2011.8-2013.6 Associate Professor, Cardiovascular Medicine, Tohoku University

2013.7-Present Professor and Chairman, Cardiovascular Medicine, Kurume University

Professional Career

Yoshihiro Fukumoto is Professor and Chairman of Cardiovascular Medicine in Kurume University School of Medicine, who is also a Fellow of JCC, JCS, AHA, and ESC. Dr. Fukumoto was awarded his medical degree from Kyushu University School of Medicine, and followed this with a PhD in coronary arteriosclerosis in Kyushu University, Fukuoka, Japan. He is a president of Japanese Pulmonary Circulation and Pulmonary Hypertension Society (since April 2024), Japanese Association of Cardiac Rehabilitation (since August 2024).

Research Field

General cardiology

Pulmonary circulation

Heart failure

atherosclerosis

Cardiac rehabilitation

Papers, Books, etc. presented or published by your name

Minatsuki S, Fukumoto Y, et al. Significance of diffusing capacity of the lungs for carbon monoxide on chronic thromboembolic pulmonary hypertension. Thorax. 2026:thorax-2025-223670.

Sugiyama Y, Fukumoto Y, et al. Utility of liver stiffness for the classification of portopulmonary hypertension in precapillary pulmonary hypertension. Int J Cardiol. 2025;429:133126.

Satoh T, Fukumoto Y, et al. Hypopituitarism Induced by Continuous Infusion of PGI2 Analogues: A Case Series and the Role of ACTH Screening and Hydrocortisone Treatment. Pulm Circ. 2025;15:e70116.

Yamashita J, Fukumoto Y, et al. Effects of pulmonary endarterectomy and balloon pulmonary angioplasty in older adults with chronic thromboembolic pulmonary hypertension: A sub-analysis of the CTEPH AC registry. Int J Cardiol Heart Vasc. 2025;60:101751.

Yamaji K, Fukumoto Y, et al. Catheter-based examination for pulmonary microcirculatory function in patients with pulmonary hypertension. PLoS One. 2024;19:e0312609.

Educational Background

Prof. Jing obtained his M.D. Ph.D. degree in 1998 from Peking Union Medical College, and then participated in 2-year postdoctoral clinical fellow training at the Hospital Antoine Béclère with Professors Gerald Simonneau and Marc Humbert, in Paris-Sud Université, France. He also received the training by World Heart Federation Emerging Leaders Programme and the American College of Cardiology Global Leadership Training program in 2014.

Professional Career

Prof. Jing is the Chairman of the Cardiovascular Medicine Department, Guangdong Cardiovascular Institute. He also is the associate Editor of HEART (the BMJ family journals), Senior Editor of JACC, the President of Guangdong Society of Cardiology. Prof. Jing led more than 100s International and National project / clinical trials on the genetics and basic / clinic research on pulmonary circulation and thrombosis, he is also the lead author on the National Clinical Guideline for Pulmonary Embolism and Pulmonary Hypertension organized by Chinese Society of Cardiology. He received almost all of most important National awards for Scientist-Physicians.

Research Field

Cardiovascular Medicine

Congenital heart disease

Pulmonary Circulation

Papers, Books, etc. presented or published under your name

Clinical features and survival in Taksyasu's arteritis-associated pulmonary hypertension: a nationwide study. Eur Heart J. 2021;42(42):4298-4305.

Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension. J Am Coll Cardiol. 2022;79(15):1477-1488.

Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2024; 84(12):1092-1103.

Evaluation of recombinant human prourokinase for acute pulmonary embolism: A phase 2, randomized clinical trial. Med. 2026 Mar 30:101068.

sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension. Eur Respir J. 2026 Jan 22:2502367.

Educational Background

M.D., College of Medicine, Seoul National University, Seoul, Korea (2005)

M.S., Department of Medicine, Seoul National University Graduate School, Seoul, Korea (2013)

Ph.D., Department of Medicine, University of Ulsan Graduate School, Seoul, Korea (2018)

Professional Career

Residency & Clinical Fellowship, Dept. of Obstetrics and Gynecology (Maternal-Fetal Medicine), Seoul National University Hospital (2007–2013)

Residency & Clinical/Research Fellowship, Dept. of Pathology (Gynecologic, Pediatric & Placental Pathology), Asan Medical Center, University of Ulsan College of Medicine (2013–2020)

Postdoctoral Scholar, Dept. of Biomedical Engineering (Computational Biology), Oregon Health and Science University (2020–2022)

Clinical Assistant Professor, Dept. of Pathology, Seoul National University Hospital (2023–2026)

Clinical Associate Professor, Dept. of Pathology, Seoul National University Hospital (2026–present)

Research Field

Pediatric pathology: rare disease diagnosis, molecular pathology, and digital atlas construction for pediatric tumors and genetic disorders

Cardiovascular pathology: CRP biology in abdominal aortic aneurysm and coronary artery bypass graft remodeling

Multiplexed tissue imaging and spatial transcriptomics for digital pathology

Placental pathology: pathophysiology of MPFD, preeclampsia, and chronic inflammatory placental disorders

Papers, Books, etc. presented or published by your name

55 peer-reviewed publications (SCI/SCIE); recent highlights include:

Multiplexed imaging-driven single-cell analysis of abdominal aortic aneurysm by CRP deposition (Translational Research, 2025, 1st author)

Plasma proteome profiling of MPFD in recurrent miscarriage (Placenta, 2025, 1st author)

Spatial whole-transcriptomic analysis of CRP in abdominal aortic aneurysm (Frontiers in Immunology, 2024, 1st author)

Dual-modality multiplexed imaging for whole-slide digital pathology (Cell Reports Methods, 2023, 1st author) 2 book chapters; 13 patents (placental diagnostics, cardiovascular imaging, digital pathology AI)

Educational Background

2015-2019: Graduate School (Ph.D.), Department of Medicine, College of Medicine, Yonsei University

2001-2007: College of Medicine, Inje University

Professional Career

2023.3- : Associate professor, College of Medicine, Hanyang University

2019-2023: Assistant professor , College of Medicine, Hanyang University

2016-18: Clinical lecturer, Asan medical center

2012-15: Clinical Fellowship, Severance Hospital

2007-2012 : Internship & Residentship, Sanggye Paik Hospital

Research Field

Coronary artery disease

Valvular heart disease

Heart failure

Pulmonary hypertension

Papers, Books, etc. presented or published by your name

Lee SE, Chang HJ, Sung JM, Park HB, Heo R, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Lee BK, Chun EJ, Cademartiri F, Maffei E, Marques H, Leipsic JA, Shin S, Choi JH, Chinnaiyan K, Raff G, Virmani R, Samady H, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study. JACC Cardiovasc Imaging. 2018 Oct;11(10):1475-1484. doi: 10.1016/j.jcmg.2018.04.015. Epub 2018 Jun 13. PMID: 29909109.

Kim DH, Heo R, Handschumacher MD, Lee S, Choi YS, Kim KR, Shin Y, Park HK, Bischoff J, Aikawa E, Song JM, Kang DH, Levine RA, Song JK. Mitral Valve Adaptation to Isolated Annular Dilation: Insights Into the Mechanism of Atrial Functional Mitral Regurgitation. JACC Cardiovasc Imaging. 2019 Apr;12(4):665-677. doi: 10.1016/j.jcmg.2017.09.013. Epub 2017 Dec 13. PMID: 29248661; PMCID: PMC5993562.

Educational Background

2005.3 – 2011.2, M.D. & Bachelor of Medicine, College of Medicine, Chosun University, Gwangju, Korea

2014.3 – 2016.2, Master of Medicine, Graduate School of Ulsan University, Seoul, Korea

2021.3 – 2025.2, Ph.D. in Medicine, Graduate School of Ulsan University, Seoul, Korea

Professional Career

2012.3 – 2016.3 Residency in Internal Medicine, Asan Medical Center, Seoul, Korea

2019.5 – 2021.2 Cardiology Fellowship, Inje University, Haeundae Paik Hospital, Busan, Korea

2021.3 – 2022.2 Cardiology Fellowship, Asan Medical Center, Seoul, Korea

2022.3 – 2026.3 Assistant Professor, Inje University, Haeundae Paik Hospital, Busan, Korea

2026.4 – present Associate Professor, Inje University, Haeundae Paik Hospital, Busan, Korea

Research Field

Cardiac imaging

Advanced heart failure and cardiomyopathy

Critical care cardiology

Cardiovascular genetics

Pulmonary hypertension

Papers, Books, etc. presented or published by your name

Park J. et al. Bovine pericardial versus porcine bioprosthetic mitral valves: results from a Korean Nationwide Cohort Study. Eur J Cardiothorac Surg. 2023 Jun 1;63(6):ezad165.

Park J. et al. Spontaneous Resolution of Extensive Iatrogenic Type A Aortic Dissection After Transcatheter Aortic Valve Replacement. JACC Case Rep. 2022 Apr 20;4(8):464-469.

Park J, Nam SH, et al. Long‑term outcomes and prognostic factors after aortic valve surgery in patients with Takayasu arteritis Gen Thorac Cardiovasc Surg. 2022 Nov 22.

Park J, et al. Safety concern with electrical cardioversion of persistent atrial fibrillation with slow ventricular response. Pacing Clin Electrophysiol. 2022 Aug;45(8):963-967.

Park J, Kim JH, Jeong YJ, et al. Different Clinical Features between Definite and Possible Takotsubo Syndrome in a Tertiary Referral Hospital. Cardiology. 2022;147(2):154-164.

Educational Background

College: Harvard University, 1989, A.B. (Magna Cum Laude, Biology)

Medical School: University of Chicago Pritzker School of Medicine, 1994, M.D.

Internship: University of Chicago, Internal Medicine, 1994-1995, 1996-1998

Residency: University of California San Francisco, Anesthesiology, 1995-1996

Fellowship: University of California San Diego, Pulmonary and Critical Care Medicine, 1998-2001

Professional Career

Faculty at UCSD since 2001. Fellowship program director 2009-2017. Currently, Professor of Medicine in the Division of Pulmonary, Critical Care, Sleep Medicine, & Physiology. Section Chief of Pulmonary Vascular Medicine. Medical Director of Pulmonary Thromboendarterectomy Program.

Research Field

Evaluation and treatment of pulmonary arterial hypertension

Interventional and medical management of chronic thromboembolic disease

Perioperative management following pulmonary thromboendarterectomy

Balloon pulmonary angioplasty for chronic thromboembolic disease

Clinical trials in pulmonary hypertension

Papers, Books, etc. presented or published by your name

As of Nov 2025: 132 peer-reviewed publications on pulmonary hypertension including, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Lead author for the 5th, 6th, and 7th World Symposium on Pulmonary Hypertension task force on “Chronic Thromboembolic Pulmonary Hypertension”. 4th World Symposium on Pulmonary Hypertension task force member: “Endpoints and Clinical Trial Design in PAH” and “Interventional and Surgical Modalities of Treatment in PH”.

Educational Background

1976 – 1978 Premedical Course, Tokyo Medical and Dental University, Chiba, Japan

1978 – 1982 M.D., Tokyo Medical and Dental University, Tokyo, Japan

2000 Ph.D. (Doctor of Medicine), Tokyo Medical and Dental University, Tokyo, Japan

Professional Career

1991 Board certified in Pediatrics, Japanese Pediatric Society

2011 Board certified in Pediatric Cardiologist, Japanese Society of Pediatric Cardiology and Cardiac Surgery

2011 Board certified in PALS provider, American Heart Association

Research Field

Japanese Medical Specialty Board and Instructor of Pediatrics

Specialty Board of Pediatric Cardiology

Honorary fellow of Japanese Society of Pediatric Cardiology and Cardiac Surgery

Honorary fellow of Japanese Pulmonary Circulation and Pulmonary Hypertension Society

Papers, Books, etc. presented or published by your name

Implantable Cardioverter Defibrillator for Primary Prevention in Children With Arrhythmogenic Right Ventricular Cardiomyopathy: A Case Series. Cureus. 2025 Jan 10;17(1):e77253

Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries. J Clin Med. 2026 Jan 30;15(3):1087. doi: 10.3390/jcm15031087